US equities |
GOOGL $283.82 ▼-12.64% GOOG $282.32 ▼-12.29% MU $934.27 ▼-4.98% MSFT $530.14 ▼-0.16% AMZN $243.79 ▼-4.25% META $624.52 ▲+1.96% NVDA $213.66 ▼-0.80% AAPL $348.91 ▲+1.48%
FinancialContent

Articles published by Amplia Therapuetics Limited

News headline image
Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib
From Amplia Therapuetics Limited
Via GlobeNewswire
Tickers ASX:ATX INNMF
News headline image
Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
From Amplia Therapuetics Limited
Via GlobeNewswire
Tickers ASX:ATX INNMF
News headline image
Accent Trial Mature Data Presented at International Conference
From Amplia Therapuetics Limited
Via GlobeNewswire
Tickers ASX:ATX INNMF
News headline image
Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial
From Amplia Therapuetics Limited
Via GlobeNewswire
Tickers ASX:ATX INNMF
News headline image
Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models
From Amplia Therapuetics Limited
Via GlobeNewswire
Tickers ASX:ATX INNMF
News headline image
Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial
From Amplia Therapuetics Limited
Via GlobeNewswire
Tickers ASX:ATX INNMF
News headline image
Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025
From Amplia Therapuetics Limited
Via GlobeNewswire
Tickers ASX:ATX INNMF
News headline image
NARMAFOTINIB Large-Scale Manufactre Complete
From Amplia Therapuetics Limited
Via GlobeNewswire
Tickers ASX:ATX INNMF
News headline image
ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM
From Amplia Therapuetics Limited
Via GlobeNewswire
Tickers ASX:ATX INNMF
News headline image
Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium
From Amplia Therapuetics Limited
Via GlobeNewswire
Tickers ASX:ATX INNMF
News headline image
Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors
From Amplia Therapuetics Limited
Via GlobeNewswire
Tickers ASX:ATX INNMF
News headline image
Additional Confirmed Response Reported as Part of Amplia Investor Presentation
From Amplia Therapuetics Limited
Via GlobeNewswire
Tickers ASX:ATX INNMF
News headline image
Key Narmafotinib Patent Granted in the U.S.
From Amplia Therapuetics Limited
Via GlobeNewswire
Tickers ASX:ATX INNMF